Quick Answer
Quoin Pharmaceuticals, Ltd. reported Net Income Loss of -$15.80 million for the year ending 2025.
- Quoin Pharmaceuticals, Ltd. showed a decrease of -76.3% in Net Income Loss from 2024 to 2025.
- This data is from Quoin Pharmaceuticals, Ltd.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$1.68 million | Q2 2022: -$2.67 million | Q3 2022: -$3.03 million | Q1 2023: -$2.60 million | Q2 2023: -$2.11 million | Q3 2023: -$1.93 million | Q1 2024: -$2.33 million | Q2 2024: -$1.97 million | Q3 2024: -$2.35 million | Q1 2025: -$3.81 million | Q2 2025: -$3.70 million | Q3 2025: -$3.95 million.
- Over the full 7 years of available data (2019 to 2025), Quoin Pharmaceuticals, Ltd.'s Net Income Loss has declined by 912.9%.
- Historical annual values: Fiscal year 2025: -$15.80 million | Fiscal year 2024: -$8.96 million | Fiscal year 2023: -$8.69 million | Fiscal year 2022: -$9.38 million | Fiscal year 2021: -$21.46 million | Fiscal year 2020: -$2.10 million | Fiscal year 2019: -$1.56 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: